Ceesay Abraham 4

What Happened

• Ceesay Abraham, CEO of Rapport Therapeutics (RAPP), sold a total of 10,916 shares in open-market transactions on February 18, 2026, generating approximately $320,373 in proceeds. The filing reports four sale lots with reported (weighted-average) prices of $29.05, $29.80, $29.04 and $29.80 per share, respectively.

Key Details

• Transaction date: February 18, 2026; Form 4 filed February 19, 2026 (timely).
• Lots sold: 3,552; 2,281; 2,983; and 2,100 shares (total 10,916).
• Reported proceeds (sum): ~$320,373.
• Reported per-lot prices (weighted averages): $29.05, $29.80, $29.04, $29.80.
• Actual sale prices occurred across multiple executions — ranges reported roughly between $28.51 and $30.09 across the lots; the filer offers to provide exact per-price counts on request.
• Footnote: Transactions were effected under pre-established Rule 10b5-1 trading plans adopted December 12, 2024.
• Ownership after the trades is not specified in the provided data; the filing includes trust-related disclaimers that some shares are held by family irrevocable trusts (the filer disclaims beneficial ownership of those trust-held shares except to the extent of any pecuniary interest).

Context

• These were sales (S) executed under a 10b5-1 plan, which are pre-set trading plans that allow insiders to sell shares at predetermined times and are generally viewed as routine rather than a direct signal of near-term insider sentiment. No options exercise, gifts, or tax-withholding events are reported in the supplied transactions.